**Understanding Medicines in Rare Forms of Aspergillosis:

A Complete Guide for Patients with CPA, ABPA, SAFS and Aspergillus Bronchitis**

People living with chronic or allergic forms of aspergillosis often face treatments that fall outside the standard medicine licensing system. You may hear terms like off-label, unlicensed, specials medicines, or rare disease. This guide explains these concepts clearly and safely in a way that helps you feel informed and confident in your care.

⭐ 1. What is a rare disease?

In the UK and EU, a rare disease is defined as:

A condition affecting fewer than 1 in 2,000 people
(≈ fewer than ~33,500 people in the UK)

Although each rare disease affects relatively few people, over 7,000 rare diseases exist, so collectively they affect 1 in 17 people.

⭐ 2. Are CPA, ABPA, SAFS and Aspergillus Bronchitis rare diseases?

Here is how the main Aspergillus-related conditions compare to the rare-disease definition.

Chronic Pulmonary Aspergillosis (CPA)

~3,600 diagnosed UK patients (under-diagnosis likely, but still rare).
✔ CPA is officially recognised as a rare disease.

Allergic Bronchopulmonary Aspergillosis (ABPA)

Occurs in 2.5–5% of all people with asthma.
UK estimate: 125,000–250,000 patients.
✘ ABPA is NOT a rare disease (but it is under-recognised).

Severe Asthma with Fungal Sensitisation (SAFS)

~8,000 estimated UK cases.
✔ SAFS meets the definition of a rare disease.

Aspergillus Bronchitis

Likely <10,000 UK patients.
✔ Aspergillus Bronchitis qualifies as a rare disease.

⭐ Summary Table

Condition	Approx UK Patients	Rare Disease?
CPA	~3,600	✔ YES
ABPA	125,000–250,000	✘ NO
SAFS	~8,000	✔ YES
Aspergillus Bronchitis	<10,000	✔ YES

Understanding whether a condition is rare helps explain why some treatments fall outside standard licensing.

⭐ 3. What is “off-label” prescribing?

Every medicine has a licence describing:

the condition it treats
dose
age group
how long it can be used
route (tablet, injection, inhaler)

Off-label means a doctor uses a licensed medicine in a way not included in the licence.

This can mean:

different disease
different dose
different age group
different route
different duration

Off-label prescribing is safe, legal, common and essential, especially in rare diseases.

⭐ 4. What is an “unlicensed” medicine?

An unlicensed medicine is one that has no UK licence at all.

Examples:

a medicine made specially for one patient (“specials”)
a liquid formulation when only tablets are sold
imported medicines licensed in another country
alternatives for patients with drug allergies

Unlicensed does not mean unsafe — it means the medicine isn’t commercially licensed in the UK.

⭐ 5. Why are off-label and unlicensed medicines common in rare diseases?

Rare diseases like CPA, SAFS and Aspergillus bronchitis:

affect small patient numbers
often have no licensed treatment
rely on specialist expertise and experience
require individualised dosing
cannot wait for slow or expensive licensing processes

Without off-label and unlicensed medicines, many rare-disease patients would have no treatment options.

This is why specialist centres exist.

⭐ 6. Biologics for ABPA: NOT licensed, but safe and widely used

This is a key point for patients.

❗ No biologic is licensed for ABPA

(as of 2025)

Not licensed for ABPA:

Omalizumab (Xolair)
Mepolizumab (Nucala)
Benralizumab (Fasenra)
Dupilumab (Dupixent)

All biologics used in ABPA are therefore off-label.

⭐ Why do specialists use them anyway?

Because evidence is strong that biologics:

reduce ABPA flare-ups
reduce steroid need
improve lung function
improve symptoms
control eosinophilic/IgE-driven inflammation
reduce hospital admissions

ABPA lacks a commercially licensed biologic
→ but specialist evidence supports them strongly.

This is high-quality off-label prescribing.

⭐ 7. How do doctors decide what evidence is “good enough”?

Doctors use several acceptable forms of evidence, including:

✔ Randomised controlled trials

✔ National/international guidelines

✔ NAC / BTS / ECCMID / IDSA specialist protocols

✔ Observational studies and real-world evidence

✔ Case series and case reports

✔ Pharmacological reasoning (mechanisms of disease)

✔ MDT (multidisciplinary team) agreement

✔ Expert clinical experience (important in rare diseases)

All of these count as legitimate evidence.

Rare-disease medicine relies on the best available evidence, not only the “highest-level” evidence.

⭐ 8. Who holds responsibility if something goes wrong?

The prescriber carries responsibility, even for:

off-label use
unlicensed medicines
imported medicines
specials items

They must:

justify the decision
explain risks and benefits
obtain consent
document
monitor

If they follow guidance, they are fully protected by:

NHS indemnity
GMC standards
Trust governance

Patients are not responsible for adverse outcomes.

⭐ 9. Is this risky for the doctor?

Only if done unsafely.

When the doctor:

✔ follows specialist guidelines
✔ explains the situation
✔ documents their reasoning
✔ uses MDT support
✔ monitors closely

…the risk is minimal and fully protected.

In rare diseases, NOT prescribing off-label can be riskier if it denies a patient effective treatment.

⭐ 10. How are patients protected?

Patients with CPA, ABPA, SAFS or Aspergillus bronchitis are protected by:

careful MDT assessment
specialist supervision
decades of centre experience
guideline-supported decisions
regular reviews and monitoring
clear communication and consent
NHS governance systems

Your care is safe, structured and evidence-based.

⭐ Final reassurance for Aspergillosis patients

If you have CPA, ABPA, SAFS or Aspergillus bronchitis:

You are not receiving “experimental” treatment.
Off-label or unlicensed medicines are normal, safe, and essential.
Your specialist team carries the responsibility for these decisions.
Biologics for ABPA are off-label because licensing is slow — not because they are untested.
You are protected by national standards, MDTs, and specialist expertise.
Your treatment is based on the best available evidence, even when the condition is rare.

This is expert, modern care designed to give you the best possible outcome.

by GAtherton

Understanding Mucous Casts in Allergic Bronchopulmonary Aspergillosis (ABPA)

People living with Allergic Bronchopulmonary Aspergillosis (ABPA) often notice thick, unusual mucus coming up during a flare. Some of this mucus can look very different from “normal” sputum and may be described as mucous casts. This leaflet explains what they are, why they happen, and what they mean for your ABPA.

⭐ What are mucous casts?

A mucous cast is a thick, sticky plug of mucus that forms inside your airways.
It takes on the exact shape of the airway or branch it was sitting in – a bit like a soft mould of the inside of your lungs.

When coughed up, casts may look:

long and tube-shaped
soft and rubbery
curled or C-shaped
occasionally branching, like a twig
pale yellow/cream with darker specks

These darker flecks can include dead inflammatory cells, airway debris, and sometimes tiny amounts of fungal material trapped inside.

⭐ Why do they happen in ABPA?

ABPA is not an infection, but an allergic over-reaction to the Aspergillus fungus.
This allergic inflammation causes:

1. Excess mucus production

Your airways create far more mucus than usual.

2. Thicker, stickier mucus

Inflammation changes the chemistry of the mucus, making it harder to clear.

3. Swollen, narrowed airways

This makes it easy for mucus to get stuck and form plugs.

4. Trapped material

Casts can contain:

fungal spores
inflammatory cells
dust or other inhaled particles
old blood or tissue debris

All of this can glue together into a cast.

⭐ Are mucous casts harmful?

They are not dangerous on their own, but they can cause problems:

Airway blockage → breathlessness, wheeze, sudden tightness
Chest infections → trapped mucus is an ideal place for bacteria
ABPA flare-ups → casts often appear during periods of high inflammation
Reduced airflow on CT scans → seen as “bronchial impaction”

Telling your clinical team when you notice casts helps them judge how active your ABPA is.

⭐ What do mucous casts look like in ABPA?

Patients often describe:

“noodles”
“worms”
“rubbery plugs”
“little branches”
“specks of brown/black” within pale mucus

These appearances are normal in ABPA and do not mean your lungs are permanently worsening.

⭐ How are mucous casts managed?

1. Airway clearance

This is the most important step. Techniques include:

huff-coughing
active cycle of breathing
nebulised saline (hypertonic or isotonic)
flutter/PEP devices (Acapella, Aerobika)
chest physiotherapy

These help loosen and move mucus from deeper airways.

2. Medication

Depending on your treatment plan:

inhalers (bronchodilator + inhaled steroids)
biologics (e.g., mepolizumab, dupilumab, omalizumab)
antifungal medication if prescribed as part of your ABPA care
oral steroids if medically appropriate

Biologics can reduce the inflammation that causes casts, so many patients notice fewer plugs over time.

3. Monitoring

Your team may keep an eye on:

sputum samples
IgE levels
CT scan changes
symptom patterns

⭐ When should I tell my team?

Contact your clinical team if you notice:

more frequent mucous casts
sudden breathlessness or chest tightness
a drop in your usual oxygen saturation
fever or signs of infection
coughing up blood
a change in colour or smell of mucus

⭐ Reassurance

Mucous casts are very common in ABPA.
They can look alarming, but they are simply a sign that your airways are inflamed and producing thick mucus.

Coughing them out is helpful, not harmful.
It allows the affected airway to reopen and can rapidly improve breathing.

✅ Further Reading

For more patient-oriented information, you can visit the AFIT website where the term “casts” is discussed in the context of aspergillosis: Aspergillus.org.uk – search “casts”.

by GAtherton

🌿 Your Immune System, Biologics, and Steroids: What’s Suppressed — and What Stays Strong

A clear, reassuring guide for people living with ABPA, CPA, asthma, SAFS, or bronchiectasis

Treatments for aspergillosis-related conditions often involve steroids, and more recently, biologics.
Many patients understandably wonder:

What do these medicines suppress?
Do they affect my ability to fight infection?
Why are biologics considered safer than long-term steroids?
Which parts of my immune system stay strong?

This guide explains the full picture in simple terms.

🧬 1. Understanding Your Immune System: The Three Layers

Your immune system has three major lines of defence.

⭐ A. Barriers — the first line

These stop pathogens entering in the first place:

Skin
Mucus in airways
Cilia sweeping mucus out
Tears, saliva, stomach acid
Healthy bacteria (microbiome)

👉 Biologics do NOT affect barriers.
👉 Steroids can weaken skin and airway lining if used long-term.

⭐ B. Innate immunity — fast responders

These act within minutes or hours.

Key cells:

Neutrophils → main killers of Aspergillus
Macrophages → engulf spores
Dendritic cells → show pathogens to T-cells
NK cells → kill virus-infected cells

Sensors:

Dectin-1 → recognises fungal walls
TLRs
Complement proteins

👉 Biologics do NOT weaken these.
👉 Steroids weaken several key functions, especially neutrophils and macrophages.

⭐ C. Adaptive immunity — targeted, long-term defence

Slower but specialised.

T-cells:

Th1 → fight bacteria/viruses
Th17 → major antifungal fighters
Th2 → allergic pathways (IgE, eosinophils)
Tregs → calm inflammation

B-cells & antibodies:

IgG / IgA / IgM → normal infection defence
IgE → allergy and ABPA pathway

👉 Biologics only suppress Th2/IgE pathways.
👉 Steroids suppress many T-cell and B-cell functions, not just allergy.

🎯 2. What Biologics Suppress (Targeted & Selective)

Biologics used in ABPA and difficult asthma (omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab) only turn down allergic inflammation, not infection-fighting immunity.

🔻 A. They suppress:

IgE
Eosinophils
IL-4 / IL-5 / IL-13
Type-2 allergic inflammation
Mucus hypersecretion (IL-13)
TSLP airway alarm signalling

🛡️ B. They do NOT suppress:

Neutrophils
Macrophages
Th1 immunity
Th17 antifungal pathways
T-cell killing function
Antibiotic/cell-mediated defences
Complement
Dectin-1 fungal recognition

This is why biologics do NOT increase fungal infection risk.

🔥 3. What Oral Steroids Suppress (Broad & Non-Specific)

Oral steroids like prednisolone reduce inflammation everywhere — including places you need for infection defence.

❌ A. They suppress key immune cells

Neutrophils → move slower, kill less effectively
Macrophages → reduced pathogen killing
T-cells → weaker antiviral/antifungal defence
B-cells → reduced antibody production

❌ B. They suppress important cytokines

IL-1, IL-2, IL-6
TNF-α
Interferons
IL-12, IL-23 (Th1/Th17 pathways)

These are essential for fighting viruses, bacteria, and fungi.

❌ C. They weaken antigen presentation

Dendritic cells and macrophages become less effective at “showing” pathogens to T-cells.

❌ D. They weaken barriers

Thinner skin
Thinner airway lining
Slower wound healing

This increases infection risk.

❌ E. They reduce eosinophils and IgE (similar to biologics)

But they do this alongside suppressing many healthy parts of your immune system.

🛡️ 4. What Remains Intact on Each Treatment

✔ On biologics (strongest preserved immunity):

Neutrophil antifungal killing
Macrophage function
Th1 & Th17 immunity
Antibodies (IgG, IgA, IgM)
Complement
Mucus & cilia defences
NK cell antiviral defence
Fever & inflammation responses

⚠️ On steroids (weaker preserved immunity):

Complement
Some antibody production
Basic barrier function (though thinner)

Many infection-fighting cells work less effectively.

🫁 5. Why Biologics Are Safer Long-Term for ABPA/SAFS

Because biologics:

target only a tiny portion of immunity
do not increase fungal growth
do not raise infection risk
reduce inflammation without broad suppression
help avoid long-term steroid complications

Steroids:

increase infection risk
can worsen fungal colonisation
damage lung structure over time
cause weight gain, bone thinning, adrenal issues
must be used short-term only when essential

🌈 6. Summary Table

Immune Feature	Biologics	Steroids
IgE suppression	✔	✔
Eosinophil suppression	✔	✔
Neutrophils	Unaffected	Suppressed
Macrophages	Unaffected	Suppressed
Th1/Th17 antifungal pathways	Unaffected	Suppressed
Viral defence	Unaffected	Suppressed
Barrier integrity	Unaffected	Weakened
Infection risk	No increase	Increased
Long-term safety	High	Low

🌟 7. One-Sentence Takeaway

Biologics turn down the allergic part of immunity (IgE, IL-4, IL-5, IL-13, eosinophils), while steroids suppress many of the infection-fighting parts as well — which is why biologics are much safer long-term.

by GAtherton

❤️ Thinking About Donating Blood After Aspergillosis or Lung Treatment?

A supportive message for people living with ABPA, CPA, SAFS, and related lung conditions

When you live with aspergillosis or a long-term lung condition, you know what it means to go through difficult treatments, long recoveries, and moments of uncertainty.
So when someone says, “Once I’m well, I’d like to donate blood to help others,” it is an incredibly generous and hopeful act.

Many people in our community wonder whether blood donation is possible after lung surgery, long-term inhalers, antifungals, or biologics. The reassuring answer is:

👉 Yes — some aspergillosis patients can donate blood once fully recovered, but it depends on individual treatments and health status.

And even if you can’t donate, the spirit behind the idea is powerful and meaningful.

🌱 1. Recovery comes first — your health is the priority

Whether you’ve had:

ABPA flare-ups
CPA treatment
bronchoscopy
long-term antifungals
biologics
a lobectomy or wedge resection

…the NHS will want you to be:

fully healed
breathing comfortably
stable in your lung condition
free from infection
strong enough to safely donate

For major surgery like a lobectomy, this often means several months of recovery before you can even be reviewed for donation.

This protects your health, not just the receiver’s.

💊 2. Medications commonly used for aspergillosis can affect eligibility

NHS Blood and Transplant will look closely at what you’re taking.

Here’s a simple guide:

Often NOT permitted

Biologics (e.g., mepolizumab, benralizumab, dupilumab)
Long-term immunosuppressants
Regular systemic steroids

May require a delay after stopping

Itraconazole / voriconazole / posaconazole
Recent antibiotic courses
Short steroid bursts

Usually fine

Inhalers
Nebulised saline
Montelukast
Airway clearance treatments
Most pain medicines

Every case is assessed individually — there is no automatic “yes” or “no” for all aspergillosis patients.

🫁 3. Your lung condition does not automatically exclude you

Having ABPA, CPA, bronchiectasis, or SAFS does not automatically prevent blood donation.

What matters is:

your condition is stable
your oxygen levels are good
you are not prone to sudden flare-ups
you feel well and strong

Many people with asthma or mild-to-moderate bronchiectasis still donate safely.

🩸 4. Your blood type is always valuable

Whether you’re a universal donor type (O-negative) or any other type, your blood can help save lives.

Even wanting to donate is something to be proud of — especially after everything you’ve been through.

🌟 5. The intention to donate speaks volumes about your strength

People living with aspergillosis know:

what it means to struggle for breath
how it feels to wait for test results
the exhaustion of flare-ups
the courage needed for surgery
the patience required for long-term treatment

So when someone in this community says:

“If I recover well, I want to donate blood to help someone else.”

…it’s a truly inspiring message of recovery and generosity.

🌈 6. Even if you can’t donate — your kindness still matters

Because of medications or long-term conditions, some people with aspergillosis will be told they can’t donate blood. This is completely normal.

You can still help others by:

encouraging friends or family to donate
sharing your story to raise awareness
supporting patient groups, campaigns, and research
simply being there for someone newly diagnosed

Your contribution to the world is not measured by a needle — it’s measured by your compassion.

❤️ Takeaway message

If you want to donate blood after aspergillosis treatment or lung surgery, that’s a beautiful intention. When you’re fully recovered, the NHS can review your health and medications. Whether you can donate or not, the willingness to help others already makes a real difference.

by GAtherton

🌿 ABPA: Infection, Allergy, Biologics, and What It All Means for You

A calm, supportive guide for patients living with Allergic Bronchopulmonary Aspergillosis (ABPA)

Allergic Bronchopulmonary Aspergillosis (ABPA) can be confusing.
Some people hear “fungus” and think it is a dangerous infection.
Others hear “allergy” and think it has nothing to do with fungi at all.

The truth is somewhere in the middle — and understanding this can make your treatment feel much clearer and less frightening.

This article explains:

Whether ABPA is an infection, an allergy, or both
How the fungus Aspergillus fumigatus fits into the picture
Why biologics help — and whether they allow the fungus to grow
Why your future with ABPA is more hopeful than ever

🌼 1. Is ABPA an infection or an allergic over-reaction?

The simplest explanation is:

ABPA happens when Aspergillus lives in mucus in the airways, and the immune system overreacts. It’s driven by allergy, not by fungal invasion.

In ABPA:

Aspergillus fumigatus sits in mucus, especially in asthma, bronchiectasis or cystic fibrosis
It does not invade or damage lung tissue
The immune system becomes over-sensitised and reacts too strongly

This allergic reaction triggers:

Very high IgE
High eosinophils
Swelling, tightness, wheeze
Thick “stringy” mucus or plugs
Repeated flare-ups that feel like chest infections

The inflammation — not the fungus — is what damages the lungs over time.

🌻 2. If it’s not a typical infection, why treat the fungus?

Even though ABPA is allergic, reducing fungal load can still help.

Here’s why:

Less fungus in mucus → less allergen
Less allergen → less immune reaction
Less reaction → fewer flare-ups, better breathing

This is why some people take antifungals.
But antifungals are not always necessary, especially today with the arrival of biologics.

🌈 3. Do biologics weaken the immune system and let the fungus grow?

No.
This is a very common worry — but the biologics used for ABPA do not suppress the parts of the immune system that keep you safe from fungi.

Biologics such as:

Omalizumab (anti-IgE)
Mepolizumab / Benralizumab (anti-IL-5)
Dupilumab (anti-IL-4/IL-13)
Tezepelumab (anti-TSLP)

target overactive allergic pathways, not antifungal defences.

They do not affect:

Neutrophils
Macrophages
Dectin-1
TLR antifungal pathways
Complement

These are the real fungus-clearing systems — and biologics leave them intact.

🍃 4. Do biologics actually help clear fungus? Surprisingly, sometimes yes.

Many patients on biologics show:

Fewer mucus plugs
Better airflow
Fewer positive sputum cultures
Reduced symptoms
Lower exacerbation rates
Less need for steroids or antifungals

When mucus plugs shrink, fungus loses its hiding place.
Your natural defences can finally clear it.

So biologics do not encourage growth — they may even help reduce fungal load.

🌺 5. Why are outcomes improving so much?

ABPA used to be a condition dominated by:

frequent flare-ups
repeated steroids
fear of lung damage
long periods of being unwell

Today, with biologics:

far fewer flare-ups
easier breathing
more stable lung function
much less steroid use
better quality of life
higher confidence and control

For many patients, biologics are transforming ABPA from a cycle of crises into a more manageable long-term condition.

🌼 6. Key reassurance

If you remember only one sentence, let it be this:

Biologics calm the allergic response that causes ABPA, without weakening your natural ability to clear fungus — and many patients do better than ever on them.

🌟 7. Moving forward with confidence

ABPA is complex, but it is treatable, manageable, and increasingly well-understood.
You are not dealing with a dangerous lung infection — you are dealing with an over-active immune response that modern treatments can control.

With the right support, airway clearance, the best inhalers, and (where needed) biologics or antifungals, most people:

stabilise
breathe more easily
reduce flare-ups
protect their lungs
live full, active lives

You’re not alone — and the future for ABPA care has never looked brighter.

by GAtherton

⭐ How to Avoid Being Fooled by Misleading Products, Private Tests and Health Claims

A practical, evidence-based guide for people living with aspergillosis, asthma, bronchiectasis and COPD

People with long-term lung conditions are often targeted by persuasive marketing, “health influencers”, alternative practitioners, and private test companies.
These services frequently exploit fear, frustration, and the very understandable desire for answers.

This expanded guide explains why certain products look scientific, why most are biologically impossible, and how you can protect yourself from being misled or spending money on things that cannot help your condition.

This is about empowerment — never about blaming patients.

🧩 1. Why misleading products look convincing

Companies deliberately use wording and imagery that trigger trust:

lab coats
microscopes
graphs and biological diagrams
words like “antifungal”, “immune”, “toxins”, “wellness”, “clinical strength”

These features make a product appear evidence-based — but appearance is not evidence.

Many claims contain a grain of truth, e.g.:

“Tea tree oil kills fungus in the lab”
“Silver has antimicrobial properties”
“This herbal extract reduces inflammation in laboratory tests”

But the missing information is the critical part:

⭐ The lab conditions have nothing to do with the human body.

To “kill fungus in a dish”, companies use concentrations that:

would be toxic in humans
cannot reach the lung tissue
would be broken down in the gut or bloodstream
do not survive into the airways

Companies rely on the fact that most customers don’t know this.

🧬 2. “Plausibility comes before testing” — the rule companies hope you don’t know

Scientists follow a simple chain:

1️⃣ Is it plausible?
Can the substance reach the lung?
Does the pathway make sense?

2️⃣ If yes — test it.
If not — don’t.

Products sold online almost always fail at Step 1.

Examples:

Turmeric supplements

Even at huge oral doses, only a tiny amount enters the bloodstream — nowhere near the lung in meaningful levels.

Oregano oil

Kills fungi on metal plates in labs — but the amount needed inside the lung would be toxic.

Silver products

Irritate the lungs and accumulate in tissues — highly implausible as therapy.

Essential oils

Break down long before reaching the airways in meaningful amounts.

Herbal antifungals

Often metabolised by the gut and liver — never reach airways at therapeutic levels.

This is why clinical trials don’t happen —
not because no one has tried,
but because there’s no scientific reason to bother.

🛍️ 3. How companies use “allowed” claims to sound medical

Because these products are not classed as medicines, they must not claim to “treat disease”.
So companies use vague, legally safe wording:

“Supports immunity”
“Maintains wellness”
“Promotes respiratory health”
“Contains antifungal botanicals”
“Helps with mould exposure”
“Advanced detox science”

All of these sound medical but say nothing measurable.

Example:

A supplement cannot say:

“Improves aspergillosis symptoms”

But it can say:

“Supports healthy immune response”

This tricks the viewer into mentally connecting the dots without the company making any illegal claims.

🧊 4. Air filters — the rare partial exception

Air purifiers can help some people, because they reduce:

dust
pollen
irritants
pet dander
airborne particulate matter

These changes may ease coughing or wheezing in sensitive people.

BUT…

most devices sold online are far too weak.

A purifier needs:

True HEPA H13 filter (not “HEPA-type”)
CADR 250–350+ for most rooms
Strong fan to turn over room air 4–5 times per hour

Without these, a purifier is just an expensive fan.

What they cannot do:

cure aspergillosis
remove Aspergillus from the lungs
prevent exposure
substitute for ventilation
fix damp or mould in walls

They improve comfort, not disease.

👩‍⚕️ 5. Why alternative practitioners are so persuasive

Alternative practitioners often:

speak with confidence
promise personalised care
provide long consultations
listen sympathetically
use scientific-sounding language
offer simple explanations for complex symptoms

Their tests and treatments look legitimate, but the problems include:

❌ No training in lung disease

❌ Misunderstanding of immunology

❌ Misuse of lab dish studies

❌ Incorrect interpretation of “toxins”

❌ Selling supplements with no evidence

❌ Recommending dangerous inhaled substances (e.g., oils, peroxide)

❌ Relying on anecdotes, not data

Even well-meaning practitioners can unintentionally cause:

lung irritation
drug interactions
adrenal effects
delays in proper NHS treatment
unnecessary fear

🧪 6. Private test companies — why their results look real but mean nothing

Common private tests include:

mycotoxin urine tests
“mould illness panels”
detox pathway testing
food IgG tests
fungal metabolite tests
heavy metal hair analysis
“immune balance” panels
testosterone finger-prick kits

These results are presented with:

charts
colour-coded ranges
expert-sounding commentary

But the key issue is:

⭐ The reference ranges are invented by the company.

Often “high” simply means:

“higher than the average of people who bought this test”

Not:

higher than healthy people
higher than unwell people
linked to disease

GPs and consultants cannot act on these results because they are not medically interpretable.

👨‍⚕️ 7. Testosterone tests — a perfect illustration of misleading health screening

Companies advertise:

“Tired? Low mood? Low motivation?”
“Check your testosterone at home”
“Feel younger again”

They use US-style messaging that implies easy treatment.

But in the UK, testosterone treatment requires:

symptoms consistent with hypogonadism
two morning venous blood tests
validated hospital labs
endocrine specialist interpretation
ruling out multiple other causes
testosterone levels fall slowly as part of ageing - it is normal

Finger-prick tests do not meet NHS criteria,
so patients end up:

anxious
misinformed
sold supplements
not eligible for NHS treatment

This perfectly mirrors the broader pattern of private testing.

🔍 8. The “curiosity gap”: why people buy tests that GPs won’t order

Patients understandably feel:

frustrated
curious
confused
not listened to
desperate for answers

When a GP says “That test won’t help,” it can feel like:

rejection
dismissal
obstruction

But the reality is:

⭐ GPs are following evidence-based pathways to protect you.

Most private tests:

do not answer a clinical question
have false positives
trigger unnecessary follow-up scans
cause anxiety
cannot be interpreted
do not influence treatment

Private companies exploit:

curiosity
frustration
the desire for answers
the emotional gap left by long waits or unexplained symptoms

But a meaningless test result is worse than no test at all.

🧾 9. Real-world examples: 15 common traps to avoid

1. Mould settle plates

All rooms grow mould on plates — totally meaningless for health.

2. IgG food sensitivity tests

Measure normal immune exposure, not allergies.

3. Finger-prick vitamin tests

Often inaccurate and label normal levels as “borderline”.

4. Lung detox drinks

Nothing you drink detoxes the lungs.

5. Hydrogen peroxide / silver nebulisers

Dangerous. Irritate lungs. Risk chemical burns and pneumonitis.

6. Essential oil diffusers marketed as “antifungal”

Irritate airways; no delivery to lung tissue.

7. Mycotoxin detox programmes

Based on non-diagnoses; push expensive supplements.

8. Immune-boosting products

No supplement boosts immunity in a useful way for aspergillosis.

9. “Black mould blood tests”

No such test exists; ranges are invented.

10. Ozone machines and air ionisers

Harmful to lungs; zero evidence.

11. Anti-mould paint additives

Mask damp; do not impact indoor fungal counts long term.

12. Red-light therapy devices

Cannot penetrate tissue; no lung benefit.

13. Detox foot patches

Turn brown from sweat; total scam.

14. Anti-mould laundry boosters

Irrelevant to aspergillus exposure.

15. Humidifiers sold for “lung support”

Raise humidity → increase mould risk.

🛡️ 10. The Anti-Fooling Checklist

Before you buy anything, ask:

✔ Has this been tested in people with aspergillosis?

✔ Can it physically reach the lungs?

✔ Does NHS medicine recognise or use it?

✔ Are the claims vague? (“supports immunity”)

✔ Are the reference ranges medically valid?

✔ Would my consultant recommend this?

✔ Is this a simple answer to a complex condition?

If any answer is no, it’s a red flag.

⭐ 11. Golden rule

If a treatment or test genuinely helped aspergillosis, your consultant would already be using it —
not influencers, Amazon sellers, or unregulated US labs.

🌟 12. Final message: It’s not foolishness — it’s human

You are not being “tricked” because you’re naïve.
These products are engineered to be emotionally irresistible.
People with chronic illness are targeted because they are thoughtful, curious, and trying hard to get better.

If you are ever unsure about a product or test:

ask NAC/CARES
ask your specialist
or bring it to your next appointment

You deserve real answers — not false hope.

by GAtherton

⭐ Recent Aspergillosis Research & Guideline Updates (Week 47)

Several important new papers on aspergillosis, diagnosis, and antifungal therapy were published this week. These include updated UK guidance, new antifungal drug targets, and insights into diagnosing invasive disease in ICU settings.

1. British Society for Medical Mycology (BSMM) Best Practice Guidance

First author: Dr Rebecca Gorton
Institution: British Society for Medical Mycology (UK)
Published: Nov 2025
Focus: Diagnosis + antifungal stewardship + clinical scenarios

Summary

This newly updated best-practice article explains how clinicians should:

combine CT scans, IgG/IgE, PCR, and galactomannan
choose antifungals appropriately
avoid misdiagnosis
apply practical recommendations to real-world cases

It is one of the most up-to-date UK-relevant guidance documents.

Why this matters for patients

Better diagnosis → faster correct treatment → fewer unnecessary antifungals.

2. Diagnostic Algorithms for Invasive Aspergillosis in ICU Patients

First author: Dr Anne-Sophie Hartmann
Institution: University Hospital Freiburg, Germany
Published: Jun 2025
Focus: ICU diagnosis & emerging risk groups

Summary

This study shows that invasive aspergillosis is increasingly found in ICU patients, including those who do not have classic risk factors.
It tests new diagnostic “pathways” combining imaging and multiple laboratory markers.

Why this matters for patients

Improves early recognition of life-threatening fungal infections in critical illness.

3. Advances in Antifungal Drug Discovery (FK1 and new targets)

First author: Dr Jonathan Miles
Institution: University of Cambridge, UK
Published: Aug 2025
Focus: New drug targets & antifungal discovery

Summary

This review outlines progress in antifungal development, including:

Fungal Kinase 1 (FK1) as a new therapeutic target
new chemical classes
failings of older antifungals
the need for next-generation medicines

Why this matters for patients

Future antifungals may be more effective, safer, and active against resistant Aspergillus.

4. British Thoracic Society (BTS) Clinical Statement on Aspergillus Lung Disease

Lead author (Chair): Dr Elizabeth Sapey
Institution: University of Birmingham / British Thoracic Society
Published: May 2025
Focus: Chronic Aspergillus disease (CPA, ABPA, SAFS, Aspergillus bronchitis)

Summary

This statement sets out national guidance to improve diagnosis and management of chronic Aspergillus-related lung disease.
It supports earlier testing, consistent management, and clearer referral pathways.

Why this matters for patients

Better recognition of CPA and ABPA
Fairer access to specialist care
More consistent treatment across the UK

5. New Antifungal Drug Classes in Development (Rezafungin, Ibrexafungerp, Olorofim)

First author: Prof David Denning
Institution: University of Manchester / NAC
Published: Sep 2025
Focus: Emerging antifungal drugs

Summary

This review discusses the latest antifungal medicines in the pipeline:

Rezafungin – long-acting IV drug
Ibrexafungerp – new oral class
Olorofim – strong activity against resistant Aspergillus

It explains mechanisms of action, clinical trial progress, and potential future roles.

Why this matters for patients

New drugs are on the way to treat resistant and difficult Aspergillus infections.

📘 Summary Table (with authors & institutions)

Title/Topic	Date	First Author	Institution	Key Focus
BSMM Best Practice	Nov 2025	Dr Rebecca Gorton	British Society for Medical Mycology (UK)	Diagnosis & stewardship
ICU Diagnostic Algorithms	Jun 2025	Dr Anne-Sophie Hartmann	University Hospital Freiburg, Germany	ICU diagnosis
New Antifungal Drug Targets (FK1)	Aug 2025	Dr Jonathan Miles	University of Cambridge	Drug discovery
BTS Clinical Statement	May 2025	Dr Elizabeth Sapey	University of Birmingham / BTS	Chronic Aspergillus disease
New Antifungal Classes (Rezafungin/Olorofim)	Sep 2025	Prof David Denning	University of Manchester / NAC	New drug development

💬 Overall Takeaway for Patients

Recent publications show strong progress:

Diagnosis is improving, especially in ICU and chronic disease clinics.
New antifungals are progressing, including drugs designed specifically to address resistance.
UK-specific guidance is strengthening, helping ensure more consistent, high-quality treatment for ABPA, CPA, SAFS, and Aspergillus bronchitis.

This is a period of rapid advancement in aspergillosis care, and the findings highlighted here directly support better outcomes for patients.

by GAtherton

ECFG 2025: Key Aspergillus and Antifungal Insights for Patients and Clinicians

The European Conference on Fungal Genetics (ECFG 2025) gathered the leading fungal biology teams from across the world. Although primarily a genetics meeting, several abstracts offered direct clinical relevance for people living with aspergillosis or those working in the field.

The research covered here focuses on:

Aspergillus fumigatus
mechanisms of disease
resistance to antifungals
emerging antifungal treatments
environmental drivers of disease
insights relevant to CPA, ABPA, SAFS, bronchiectasis and invasive aspergillosis

Summary of Key Themes

1. Aspergillus genetic diversity is much greater than assumed

Pangenome work showed A. fumigatus strains possess different virulence genes and resistance traits. This may explain differences in how patients respond to infection and medication.

2. Environmental azole resistance continues to rise

Multiple abstracts confirmed that resistant strips often originate outdoors, shaped by climate, fungicides, soil chemistry, and climate change.

3. Promising new antifungals are advancing

Manogepix shows excellent activity against resistant strains, while several early-stage compounds (such as G-quadruplex ligands) represent brand-new modes of action.

4. Insights into virulence, persistence and treatment failure

Studies on hyphal fusion, echinocandin tolerance, and hypoxia adaptation shed light on chronic and resistant infections.

5. Improved tools accelerate antifungal discovery

CRISPR and genus-wide sequencing speed up the search for new drug targets and better diagnostics.

ECFG 2025 — Table of All Aspergillus / Aspergillosis / Antifungal-Relevant Abstracts

ID	Title	Lead Author / Presenter	Institution	Category	Why It Matters
WS1.19	Reference pangenomes for A. fumigatus	Marion Perrier	Friedrich Schiller University, Jena	Genomics / Evolution	Reveals hidden genetic diversity linked to virulence and resistance.
WS1.20	Antifungal modes of action of G-quadruplex ligands	Isabelle Storer	University of East Anglia	New antifungal mechanisms	Suggests a brand-new antifungal class targeting fungal DNA structures.
WP1.2	NL1 as anti-virulence compound	Jorge Amich	ISCIII, Spain	Virulence / Therapeutics	May reduce disease severity without relying on killing the fungus.
WP1.6	Ace2 and RAM pathway regulation	Devi N. J. Bale	—	Pathogenesis	Controls tissue invasion, morphology and possibly drug sensitivity.
WP1.8	Hyphal fusion and multi-drug resistant heterokaryons	Michael Bottery	University of Manchester	Resistance mechanisms	Shows resistance traits may spread between strains via fusion.
WP1.10	Manogepix activity against A. fumigatus	Sean Brazil	Trinity College Dublin	New antifungals	Strong activity including against resistant strains and biofilms.
WP1.14	ZfpA and echinocandin tolerance	Dante Calise	University of Wisconsin	Echinocandin tolerance	Explains how fungi sometimes survive caspofungin and related drugs.
WP1.16	Genetic background of azole-resistant A. fumigatus	Saioa Cendón-Sánchez	University of the Basque Country	Environmental resistance	Confirms resistant genotypes circulate between the environment and patients.
WP1.18	Genus-wide sequencing of Aspergillus	Ronald P. de Vries	Westerdijk Institute	Evolution / Pathogenicity	Identifies traits making some species pathogenic to humans.
WP1.22	Climate, soil & fungicide impacts on Aspergillus	Thomas Easter	University of Manchester	Environmental epidemiology	Links climate change and fungicides to rising azole resistance.
WP1.32	Multiplex CRISPR to accelerate antifungal research	Fabio Gsaller	—	Research tools	Speeds identification of resistance pathways and drug targets.
WP1.42	Hypoxia-driven adaptations in A. fumigatus	Olaf Kniemeyer	—	Pathogenesis	Explains persistence of A. fumigatus in low-oxygen lung cavities (CPA).

Detailed Clinical Relevance of the Findings

1. Rising environmental resistance

Azole-resistant A. fumigatus continues to emerge in agricultural and urban settings. Resistant spores are carried in air and soil, meaning people inhale them in daily life. This is especially relevant to those with CPA, ABPA, bronchiectasis and immunosuppression, who are more vulnerable.

Why it matters:
Resistant strains are a growing cause of treatment failure.

2. New antifungal treatments are progressing

Manogepix shows potent activity against resistant Aspergillus and biofilms, key in difficult-to-treat CPA and invasive aspergillosis.

G-quadruplex ligands and NL1 represent early steps toward new antifungal classes, extremely important after two decades of limited drug options.

3. Virulence and survival mechanisms explain persistent disease

Hypoxia adaptation (low-oxygen survival) helps explain why Aspergillus persists in lung cavities.
Hyphal fusion may allow rapid spread of resistance traits.
Echinocandin tolerance mechanisms (ZfpA) reveal why some invasive cases fail to respond.

Why it matters:
These insights help clinicians anticipate treatment difficulties and inform research for new therapies.

4. Better genomic tools support faster discovery

Multiplex CRISPR and pangenomic databases allow scientists to uncover gene functions much faster. This shortens the path to new antifungal development and improves understanding of how resistance evolves.

Conclusion

ECFG 2025 provides important clues about why Aspergillus disease is so persistent, why azole resistance is increasing, and how new antifungal drugs may overcome today’s challenges. It also reinforces that environmental drivers — including fungicide use and climate factors — are a major part of the problem.

For patients, clinicians, and researchers, these findings highlight a rapidly evolving landscape in aspergillosis research, with promising signs of future treatment improvements.

by GAtherton

TIMM 2025 – Aspergillosis-Relevant Highlights for Non-Specialist Professionals

BRIEFING: Key Aspergillosis Themes from TIMM 2025

(For non-specialist professionals and patient advocates)

The 2025 TIMM abstracts show continuing concern around rising azole resistance, emerging Aspergillus species, and ongoing diagnostic challenges in chronic and invasive disease. A growing number of studies highlight the importance of environmental surveillance, molecular diagnostics, and recognising less typical at-risk groups such as people with viral pneumonias, COPD, and those receiving new biologics or immunomodulators.

Clinical messages for non-specialists:

1. Environmental and agricultural azole use remains a major resistance driver

Multiple studies (Latin America, Spain, Belgium) confirm that agricultural triazoles continue to select for resistant Aspergillus fumigatus. Resistant strains do reach hospital environments, including ICUs and haematology wards.

Implication:
Healthcare teams must remain alert to azole treatment failure, consider susceptibility testing, and recognise that resistance is no longer rare.

2. Cryptic and emerging Aspergillus species are increasingly recognised

Traditional diagnostics often miss less common species such as A. turcosus, A. hiratsukae, and A. pseudodeflectus.
MALDI-TOF may misidentify these species; molecular sequencing gives clearer answers.

Implication:
If disease progresses unexpectedly or does not respond to standard therapy, consider the possibility of an unusual Aspergillus species.

3. New risk groups for invasive aspergillosis

Studies from Europe highlight increasing cases of IA in:

Severe viral pneumonia (RSV, influenza, COVID-19)
Patients receiving modern biologics (tocilizumab, oblituzumab)
Children with haematological cancers
Lung transplant recipients (with late-onset IA)
COPD patients or those without classical immunosuppression

Implication:
Non-specialists should be aware that IA is no longer confined to neutropenia or transplant; clinicians should maintain suspicion in severely unwell respiratory patients.

4. Diagnostic testing improves when multiple methods are combined

Several abstracts show:

Combining galactomannan + PCR on BAL substantially improves detection.
Western blot + IgE/IgG pairing improves ABPA and CPA diagnosis.
ICAP alone has a very high false-positive rate.

Implication:
Do not rely on a single test. ABPA and CPA particularly require combined clinical + radiological + serological evidence.

5. Aspergillus biofilms remain important and difficult to treat

Biofilm studies show that:

Mature Aspergillus biofilms are highly drug-tolerant.
Co-habiting bacteria (e.g., Stenotrophomonas maltophilia) enhance biofilm stability.
Biofilms may explain chronic, relapsing airways disease patterns in CPA/ABPA/bronchiectasis patients.

Implication:
Patients with chronic or relapsing symptoms may have biofilm-driven inflammation and reduced antifungal penetration.

6. Mortality in invasive disease remains high

Reports from transplant units and paediatric oncology centres show:

58% mortality in paediatric invasive aspergillosis.
6% IA-related mortality in lung transplant cohort (with many later indirect deaths).
Early diagnosis and correct drug choice remain critical.

Implication:
Prompt recognition and appropriate antifungal selection (including combination therapy when needed) remain essential.

TABLE OF ALL RELEVANT ASPERGILLUS / ASPERGILLOSIS / ANTIFUNGAL ABSTRACTS

(From full-document review; includes resistance, diagnostics, epidemiology, biofilms, and case reports)

ID	Title / Topic	Type
Latin America Environment Study	Environmental azole resistance across 12 countries; 2152 A. fumigatus isolates	Environmental / Resistance
P026	A. fumigatus in Belgian hospitals: triazole resistance surveillance	Environmental / Clinical resistance
27-Year Spain Study (Ashraph et al.)	118 azole-resistant strains; multiple fungicide resistance mechanisms	Environmental / Genomics / Resistance
P317	Invasive sinus aspergillosis by A. hiratsukae in transplant recipient	Case report / Cryptic species
CPA Case – A. pseudodeflectus	Chronic necrotising CPA from rare Usti-section Aspergillus	CPA / Case
P389	Metagenomics confirming mixed Aspergillus infection (A. niger + A. terreus)	Diagnostics / Mixed infection
A. turcosus fatal IA case	Cryptic fumigati species causing fatal invasive infection	Case report / Cryptic species
P213	Difficult CPA diagnosis in COPD	CPA / Clinical
P224	Recurrent maxillary sinus aspergilloma with bone destruction	Sinus aspergillosis
P267	Epidemiology of Aspergillus-related lung disease (IPA, CPA, ABPA) in Marseille	Epidemiology
P252	Species distribution in 418 filamentous fungal infections – Aspergillus dominant	Epidemiology
Lung transplant cohort (1100 pts)	IPA incidence, risk factors, treatment outcomes	IPA / Transplant
Paediatric oncology IA cohort	43 cases; high mortality	Paediatric IA
P352	RSV-associated invasive pulmonary aspergillosis	Viral-associated IPA
Asp-WB + ICAP combination study	Improved diagnosis of ABPA/CPA; ICAP alone widely false positive	Diagnostics
Molecular vs GM vs culture study	PCR on BAL highly accurate for Aspergillus detection	Diagnostics
P154	Lateral flow assay (LFA) for Aspergillus in sputum/serum	Diagnostics
Mixed biofilm GAG study	Bacterial–fungal synergy increases biofilm resilience	Biofilms / Pathogenesis
P090	Aspergillus biofilm extracellular matrix across strains and mixed species	Biofilms
TB–fungal co-infection (Aspergillus rare but present)	7 Aspergillus co-infections among TB cohort	Epidemiology

TABLE OF ALL RELEVANT ASPERGILLUS / ASPERGILLOSIS / ANTIFUNGAL ABSTRACTS WITH SUMMARIES

ENVIRONMENTAL & RESISTANCE STUDIES

1. Latin America Environmental Study

Topic: Air sampling in 12 countries: azole-resistant A. fumigatus widely present.
Summary: Large-scale citizen-science sampling found resistant Aspergillus spores across cities, rural sites, and farms. Confirms that humans inhale resistant strains from the environment, not just healthcare settings.

**2. P026 — A. fumigatus in Belgian Hospitals**

Topic: Hospital environmental surveillance for triazole resistance.
Summary: Resistant strains were found inside clinical areas, indicating they can enter hospitals via outdoor air. Important for infection control planning and for selecting appropriate antifungal therapy.

3. 27-Year Spanish Resistance Evolution Study (Ashraph et al.)

Topic: 118 azole-resistant isolates characterised over nearly three decades.
Summary: Shows a clear link between agricultural fungicide exposure and clinical resistance. Some strains developed multi-fungicide resistance, not just medical azoles.

CLINICAL CASES & CRYPTIC SPECIES

**4. P317 — A. hiratsukae Sinusitis in Transplant Patient**

Topic: Rare Aspergillus species causing invasive sinus disease.
Summary: Standard tests misidentified the fungus. Molecular sequencing confirmed a rare species. Highlights the need for advanced diagnostics when patients fail to improve.

5. CPA Case — A. pseudodeflectus

Topic: Chronic pulmonary aspergillosis caused by an unusual species.
Summary: Routine ID methods mislabelled the organism. Demonstrates cryptic species can cause CPA and may have different antifungal patterns.

**6. Mixed A. niger + A. terreus Wound Infection (Metagenomics)**

Topic: Mixed Aspergillus infection detected only by sequencing.
Summary: Traditional culture missed the second species. Mixed infections may explain poor responses to treatment.

**7. A. turcosus Fatal IA Case**

Topic: Rare fumigati section species.
Summary: Standard MALDI-TOF misidentified the species. High mortality emphasises why correct species identification matters for appropriate antifungal choice.

8. P213 — CPA Misdiagnosed as COPD

Topic: Chronic necrotising CPA mimicking COPD exacerbations.
Summary: Symptoms and imaging resembled COPD flare-ups. Only biopsy and molecular tests confirmed CPA. Highlights need for fungal testing in patients with atypical COPD.

9. P224 — Recurrent Maxillary Sinus Aspergilloma

Topic: Aspergillus sinus infection with bone involvement.
Summary: Shows how aspergilloma can recur if fungal debris remains or anatomy predisposes to blockage. ENT review and sometimes surgery are essential.

EPIDEMIOLOGY & COHORT STUDIES

10. P267 — Aspergillus Lung Disease in Marseille

Topic: Mix of ABPA, CPA and IPA.
Summary: Many ABPA cases were untreated or misclassified. Underlines widespread under-diagnosis and need for education of clinicians.

11. P252 — Species Distribution in 418 Fungal Infections

Topic: Large clinical review of filamentous fungi.
Summary: Aspergillus was the most common mould isolated, with A. fumigatus dominating. Confirms its continuing role as the most clinically significant mould.

12. Lung Transplant Cohort (1100 patients)

Topic: IA incidence, timing, species distribution and outcomes.
Summary: Early IA occurred from colonisation or environmental exposure; late IA linked to rejection and immunosuppression. Mortality remains high.

13. Paediatric Oncology IA Cohort

Topic: 43 children with invasive aspergillosis.
Summary: Mortality 58%. Mostly in acute leukemias. Underscores need for rapid testing and early therapy in children.

14. P352 — RSV-Associated Invasive Aspergillosis

Topic: Expanding “viral-associated pulmonary aspergillosis” beyond influenza and COVID-19.
Summary: RSV can also predispose immune-competent patients to IA. Important emerging risk category.

DIAGNOSTICS

15. Asp-Western Blot + IgE/IgG Combination Study

Topic: Diagnostic accuracy for ABPA/CPA.
Summary: Combining tests improves accuracy. ICAP alone is unreliable, with high false positives.

16. Molecular vs GM vs Culture Study (Italy)

Topic: Diagnostic accuracy of PCR on BAL.
Summary: PCR in BAL fluid was the most sensitive method. Combining PCR + galactomannan gave the best results.

17. P154 — Lateral Flow Assay (LFA)

Topic: Rapid point-of-care test for Aspergillus antigen.
Summary: Good performance in pre-treated sputum and serum. Promising as a rapid triage tool.

BIOFILM & PATHOGENESIS

18. Mixed Biofilm Study — A. fumigatus + S. maltophilia

Topic: How fungi and bacteria form stabilised mixed biofilms.
Summary: The Aspergillus biofilm sugar GAG enhances bacterial adhesion. Explains why some patients have stubborn, relapsing infections.

19. P090 — Biofilm Extracellular Matrix Study

Topic: Differences in matrix structure across Aspergillus strains.
Summary: Certain strains form thicker, more drug-resistant biofilms. May explain different patient responses to the same antifungal treatment.

TB CO-INFECTION (Aspergillus-related)

20. TB + Fungal Co-infection Study

Topic: TB patients screened for fungal disease.
Summary: Aspergillus infections were rare but present. Highlights need to consider CPA in chronic post-TB lung damage.

by GAtherton

Why Join the Aspergillosis Patient Advisory Group (PAG)?

Supported by the European Lung Foundation (ELF), NAC CARES, and the European Respiratory Society (ERS).

Living with aspergillosis — CPA, ABPA, SAFS, Aspergillus bronchitis or sinus disease — can be overwhelming. Many people feel isolated, struggle to find clear information, or feel unsure how to influence the care they receive.
That is exactly why the Aspergillosis Patient Advisory Group (PAG) exists.

The PAG is supported by the European Lung Foundation (ELF) — based in Sheffield — and by NAC CARES, the patient engagement and support team at the UK National Aspergillosis Centre (NAC) in Manchester. Together, ELF, NAC CARES and the PAG work closely with the European Respiratory Society (ERS) to make sure the patient voice shapes research, education, and clinical practice across Europe and the UK.

What ELF Does

ELF brings together patients, carers, researchers and professionals from across Europe including the UK. It:

Provides clear, trustworthy patient information
Organises and hosts patient advisory groups
Ensures patient voices are included in ERS guidelines and research
Supports patient–professional workshops, surveys and consultations
Helps patients shape respiratory policy and awareness campaigns

Because ELF is UK-based, participation is easy for UK patients.

What NAC CARES Does

NAC CARES is the patient-facing team at the National Aspergillosis Centre in Manchester.
They:

Support UK patients to join the PAG
Help connect lived experience from UK clinics to the wider European PAG
Share updates, resources, and educational material
Bring PAG priorities back into NAC’s clinical and research work
Ensure UK patients feel included, represented and supported within ELF and ERS structures

NAC CARES acts as a bridge between UK clinical expertise and European patient involvement.

What the Aspergillosis PAG Does

The PAG ensures that people living with aspergillosis have a direct say in:

Research design
European Respiratory Society guidelines
New diagnostic and treatment pathways
Patient-friendly information materials
Awareness projects and health campaigns
Surveys that drive change in policy and clinical practice

Your lived experience is treated as meaningful expertise.

Why Join the PAG? Why Spend Your Energy?

Many people with aspergillosis have limited energy.
Here is why members say it is worth it:

1. You receive clear, reliable information

Updates on research, antifungals, biologics, trials and guidelines — written for patients, not scientists.

2. Your voice shapes real decisions

ERS guideline committees and research teams listen.
Your input changes how care is delivered.

3. You feel less alone

Aspergillosis is rare.
The PAG connects you with people across Europe and the UK who truly understand.

4. You choose how involved you want to be

You can simply receive updates — or you can complete the occasional survey, join a focus group, or help shape a guideline.
No pressure, no obligation.

5. It improves care for everyone — including you

Your experience helps highlight what really matters:

Delayed diagnosis
Side-effects
Treatment access
Fatigue and breathlessness
Impact on quality of life

This evidence influences clinicians, researchers and policymakers.

6. It is free, inclusive and easy to join

No travel.
No cost.
All online.
Europe includes the UK, and ELF is based in Sheffield.

Who Can Join?

Anyone affected by aspergillosis:

Patients with CPA, ABPA, SAFS, Aspergillus bronchitis or sinus disease
People with fungal allergy in asthma or bronchiectasis
Family members and carers

No medical background needed.

How to Join

You can join in a few minutes:

👉 https://europeanlung.org/en/patient-advisory-groups/
Choose “Aspergillosis”.

You’ll then receive updates and invitations to take part — always at your own pace.

In One Line:

The PAG gives you good information, a real voice in shaping aspergillosis care, and a supportive community — with full backing from ELF, ERS and NAC CARES.

by GAtherton